FDA Approves Servier's Voranigo: A Breakthrough in Low-Grade Brain Cancer Treatment

Servier has expanded its therapeutic arsenal with the FDA approval of Voranigo, a dual inhibitor targeting IDH1 and IDH2 mutations. This approval represents a significant breakthrough for treating low-grade gliomas, marking the first systemic therapy approval for grade 2 IDH-mutant brain cancer in over two decades. Voranigo is approved for both adults and children aged 12 and older, providing a new option for managing conditions such as oligodendrogliomas and astrocytomas.

Servier acquired Voranigo through its $2 billion purchase of Agios Pharma's oncology business in 2021. The drug, designed to penetrate the blood-brain barrier, showed impressive results in the phase 3 INDIGO trial, reducing the risk of tumor progression or death by 61% compared to placebo. Additionally, Voranigo demonstrated a 74% reduction in the need for further treatment, making it a promising new therapy for glioma patients. Royalty Pharma projects that Voranigo could achieve over $1 billion in annual peak sales in the U.S., underscoring its potential impact.

Before Voranigo, treatment options for IDH-mutant gliomas were outdated and limited to off-label uses of other drugs. This new approval not only provides a dedicated treatment but also opens the door for further research. Servier is exploring Voranigo's potential in combination with Merck's immunotherapy Keytruda and the chemotherapy temozolomide for more aggressive gliomas. The FDA approval has also triggered significant financial movements, with Servier owing Agios a $200 million milestone payment and Royalty Pharma committing $905 million for a 15% royalty on U.S. sales up to $1 billion.

Click here to read the original news story.